Quantcast

Latest Macular edema Stories

2014-10-17 08:25:24

TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA(®) (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both...

2014-10-09 23:00:29

Findings help product development at Diopsys, Inc. Pine Brook, NJ (PRWEB) October 10, 2014 Research scientists from the University of Alabama, Birmingham (UAB), Gladstone Institutes and University of California, San Francisco published findings in the Journal of Experimental Medicine stating there is a direct correlation with functional cell loss in the retina and signs of dementia in people with a genetic risk for frontotemporal dementia (FTD). The study shows that changes in the retina...

2014-10-09 08:27:53

CEO to Discuss Milestone FDA Approval of ILUVIEN as the First Long-Term Treatment for Diabetic Macular Edema ATLANTA, Oct. 9, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will present at the Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology (AAO) annual meeting in Chicago,...

2014-10-08 23:00:26

New study shows that the Diopsys NOVA-ERG acts as window to the brain Pine Brook, NJ (PRWEB) October 09, 2014 Research scientists from the University of Alabama, Birmingham (UAB), Gladstone Institutes and University of California, San Francisco published findings in the Journal of Experimental Medicine stating there is a direct correlation with functional cell loss in the retina and signs of dementia in people with a genetic risk for frontotemporal dementia (FTD). The study shows that...

2014-10-08 08:26:24

-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since its launch in Canada in 2007, Lucentis(®) has treated more than 100,000 eyes across all approved indications(3 ) DORVAL, QC, Oct. 8, 2014 /CNW/ - Novartis Pharmaceuticals Canada Inc. announced today that Lucentis(®) (ranibizumab), the treatment for several major causes of vision loss, has been...

2014-10-06 16:27:54

EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Macular Edema following RVO TARRYTOWN, N.Y., Oct. 6, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA(®) (aflibercept) Injection for the treatment of Macular Edema following Retinal Vein Occlusion (RVO), which includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition...

2014-09-26 16:23:57

Company will issue a more detailed announcement on Monday, September 29 ATLANTA, Sept. 26, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN(®) for the treatment of diabetic macular edema (DME) in patients who have been previously treated...

2014-09-22 04:21:43

TARRYTOWN, N.Y., Sept. 22, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA(®) (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). EYLEA has already been approved in Japan for the treatment of patients with neovascular age-related macular degeneration (wet AMD), and...

2014-09-16 08:29:26

Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA(®) (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which...

2014-09-04 04:21:42

TARRYTOWN, N.Y., Sept. 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has submitted a marketing authorization application for EYLEA(®) (aflibercept) Injection for macular edema following branch retinal vein occlusion (BRVO) to the Japanese Ministry of Health, Labour and Welfare (MHLW). EYLEA has already been approved in Japan for the treatment of patients with neovascular (wet)...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.